# 510(k) SUMMARY

# SUBMITTED BY:

BECTON, DICKINSON AND COMPANY   
10865 Road to the Cure, Suite 200   
San Diego, CA 92121   
Phone: 858-795-7890   
Fax: 858-812-8505

Gregory Payne

January 31, 2013

CONTACT NAME: DATE PREPARED: DEVICE TRADE NAME: DEVICE COMMON NAME: DEVICE CLASSIFICATION: PREDICATE DEVICES:

BD Veritor™ System for Rapid Detection of Group A Strep

Streptococcus spp. serological reagents

21 CFR $\ S$ 866.3740

Clearview Advanced ™ Strep A Test

# INTENDED USE:

The BD Veritor™" System for Rapid Detection of Group A Strep test is a rapid chromatographic immunoassay for the direct and qualitative detection of Group A Streptococcus antigen from throat swabs of symptomatic patients. It is intended to be used in conjunction with the BD Veritor " System Reader as an aid in the diagnosis of Group A Strep. All negative test results should be confirmed by bacterial culture because negative results do not preclude Group A Strep infection and should not be used as the sole basis for treatment.

The BD Veritor System for rapid detection of Group A Strep test is intended for use in point-of-care or laboratory settings.

# DEVICE DESCRIPTION:

The BD Veritor ™ System for rapid detection of Group A Strep is a qualitative, lateral flow immunoassay for the detection of Strep A carbohydrate antigen in a throat swab. In this test, antibody specific to Strep A carbohydrate antigen is coated on the test line region of the Assay device. During testing, the processed throat swab specimen reacts with an antibody to Strep A that is conjugated onto detector particles. The mixture migrates up the membrane to react with the antibody to Strep A on the membrane and is captured by the line of antibody on the membrane. A positive result for Strep A is determined by the BD Veritor ™m System Reader when antigen-conjugate is deposited at the Test "T" position and the Control "C" position on the BD Veritor ™m System Strep A assay device.

# DEVICE COMPARISON:

The BD Veritor ™M System for Rapid Detection of Group A Strep was compared to the Clearview Advanced ™ Strep A test k091489.

<table><tr><td colspan="1" rowspan="1">ProductFeature</td><td colspan="1" rowspan="1">BD Veritor™ System forRapid Detection of Group AStrep</td><td colspan="1" rowspan="1">Binax ClearviewAdvanced Strep Atest k091489</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The BD Veritor ™ System forRapid Detection of Group AStrep test is a rapidchromatographicimmunoassay for the directand qualitative detection ofgroup A Streptococcusantigen from throat swabspecimens of symptomaticpatients to aid in diagnosis ofGroup A Streptococcusinfection. It is intended to beused in conjunction with theBD Veritor ™ System Readeras an aid in the diagnosis ofGroup A Streptococcalinfection.</td><td colspan="1" rowspan="1">The Binax ClearviewAdvanced ™ Strep Atest is a rapidchromatographicimmunoassay for thequalitative detectionof group AStreptococcusantigen from throatswab specimens asan aid in thediagnosis of Group AStreptococcalinfection.</td></tr><tr><td colspan="1" rowspan="1">SpecimenTypes</td><td colspan="1" rowspan="1">Throat swabs</td><td colspan="1" rowspan="1">Throat swabs</td></tr><tr><td colspan="1" rowspan="1">AssayTechnology</td><td colspan="1" rowspan="1">Immunochromatographic</td><td colspan="1" rowspan="1">Immunochromatographic</td></tr><tr><td colspan="1" rowspan="1">DetectionFormat</td><td colspan="1" rowspan="1">An opto-electronic readerdetermines the line intensityat each of the spatially-defined test and control linepositions, interprets theresults using the scoringalgorithm, and reports apositive, negative, or invalidresult on the LCD screenbased on pre-set thresholds.</td><td colspan="1" rowspan="1">Visual determinationof presence orabsence of pink-to-red Test Line and theappearance of a blueProcedural ControlLine on the test stripindicate the presenceof Group AStreptococcalantigen.</td></tr><tr><td colspan="1" rowspan="1">Qualitative orQuantitative</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Qualitative</td></tr><tr><td colspan="1" rowspan="1">ProductFeature</td><td colspan="1" rowspan="1">BD Veritor ™ System forRapid Detection of Group AStrep</td><td colspan="1" rowspan="1">Binax ClearviewAdvanced Strep Atest k091489</td></tr><tr><td colspan="1" rowspan="1">Total Assay Time</td><td colspan="1" rowspan="1">Approximately 5 minutes</td><td colspan="1" rowspan="1">Less than 5 minutes</td></tr><tr><td colspan="1" rowspan="1">Control format</td><td colspan="1" rowspan="1">Kit Strep A positive controlswabKit Strep A negativecontrol swabInternal control lines</td><td colspan="1" rowspan="1">Kit Strep Apositive controlswabKit Strep Anegative controlswab</td></tr><tr><td colspan="1" rowspan="1">Detection ofGroup A Strep</td><td colspan="1" rowspan="1">Test will indicate thepresence of both viable andnon-viable group AStreptococcus bacteria</td><td colspan="1" rowspan="1">Test will indicate thepresence of bothviable and non-viablegroup AStreptococcusbacteria</td></tr></table>

# SUMMARY OF PERFORMANCE DATA:

# Analytical Sensitivity

The limit of detection for Streptococcus pyogenes was established with the BD Veritor™ System for Rapid Detection of Group A Strep test. The limit of detection (LOD) is defined as the lowest concentration that produces an approximate $9 5 \%$ positive reaction when tested with 60 replicates.

<table><tr><td rowspan=1 colspan=1>STRAIN</td><td rowspan=1 colspan=1>LOD(CFU/mL)</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>%Positivity</td></tr><tr><td rowspan=1 colspan=1>12384</td><td rowspan=1 colspan=1>1 x 10 }$</td><td rowspan=1 colspan=1>57/60Positive</td><td rowspan=1 colspan=1>95.0%</td></tr><tr><td rowspan=1 colspan=1>19615</td><td rowspan=1 colspan=1>5 x 104</td><td rowspan=1 colspan=1>58/60Positive</td><td rowspan=1 colspan=1>96.7%</td></tr><tr><td rowspan=1 colspan=1>25663</td><td rowspan=1 colspan=1>2 x 10 }$</td><td rowspan=1 colspan=1>57/60Positive</td><td rowspan=1 colspan=1>95.0%</td></tr></table>

# Analytical Specificity

The reactivity of various Streptococcal strains was determined with the BD Veritor™ System for Rapid Detection of Group A Strep test. Lancefield Groups A, B, C, D, F and G were tested at 1X1 $0 ^ { 9 }$ CFU/mL in triplicate and yielded negative results.

Various microorganisms (including bacteria and yeasts) that might be found in specimens were evaluated for potential cross reactivity with the BD Veritor'" System for Rapid Detection of Group A Strep test.

<table><tr><td rowspan=1 colspan=3>BD Veritor&quot; System for Rapid Detection of Group A Strep Cross ReactivityStudy Results - Bacteria and Yeast</td></tr><tr><td rowspan=1 colspan=1>Microorganism Name</td><td rowspan=1 colspan=1>ConcentrationTested</td><td rowspan=1 colspan=1>Group. A Strep TestResult</td></tr><tr><td rowspan=1 colspan=1>Arcanobacterium haemolyticum</td><td rowspan=1 colspan=1>$1x10^}$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Bordetella pertussis</td><td rowspan=1 colspan=1>5x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Candida albicans</td><td rowspan=1 colspan=1>1.x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium diphtherium sp(Corynebacterium sp)</td><td rowspan=1 colspan=1>1x10 CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecalis</td><td rowspan=1 colspan=1>$1x10^$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecium</td><td rowspan=1 colspan=1>1x10^ $CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=1>1.5x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Fusobacterium necrophorum</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenzae</td><td rowspan=1 colspan=1>$1x10^}$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Haemophilus parahemolyticus</td><td rowspan=1 colspan=1>1.2x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Haemophilus parainfluenzae</td><td rowspan=1 colspan=1>1x10^2 $CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae</td><td rowspan=1 colspan=1>1.5x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Lactobacillus sp (Lactobacilluscasei)</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Moraxella catarrhalis</td><td rowspan=1 colspan=1>$1x10^}CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Moraxella lacunata</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Mycobacterium tuberculosisavirulent</td><td rowspan=1 colspan=1>5x10 CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Neisseria gonorrhoeae</td><td rowspan=1 colspan=1>1x10^$ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Neisseria lactamica</td><td rowspan=1 colspan=1>$1x10^$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Neisseria meningitidis</td><td rowspan=1 colspan=1>1x10^$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Neisseria mucosa</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Neisseria sicca</td><td rowspan=1 colspan=1>$1x10^ $CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Neisseria subflava</td><td rowspan=1 colspan=1>1x10^CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Proteus vulgaris</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Serratia marcescens</td><td rowspan=1 colspan=1>$1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1>$1x10^$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus epidermidis</td><td rowspan=1 colspan=1>$1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus haemolyticus</td><td rowspan=1 colspan=1>$1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus anginosus</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus mitis</td><td rowspan=1 colspan=1>1x10^$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus               mutansATCC25173</td><td rowspan=1 colspan=1>3x10^CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus oralis</td><td rowspan=1 colspan=1>$1x10^}CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>$1x10^$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus salivarius</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr></table>

BD Diagnostic Systems Becton, Dickinson and Company

<table><tr><td rowspan=1 colspan=3>BD Veritor&quot; System for Rapid Detection of Group A Strep Cross ReactivityStudy Results - Bacteria and Yeast</td></tr><tr><td rowspan=1 colspan=1>Microorganism Name</td><td rowspan=1 colspan=1>ConcentrationTested</td><td rowspan=1 colspan=1>Group A Strep TestResult</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus sanguis</td><td rowspan=1 colspan=1>$1x10^}CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp.Group B</td><td rowspan=1 colspan=1>$1x10^}$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp.Group C</td><td rowspan=1 colspan=1>$1x10^{}$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp.(bovis 1I)Group D</td><td rowspan=1 colspan=1>1x10$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp. Group F</td><td rowspan=1 colspan=1>$1x10^}$CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp. Group G</td><td rowspan=1 colspan=1>1x10^ CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Yersinia enterocolitica</td><td rowspan=1 colspan=1>1x10^ $CFU/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Adenovirus Type 1.</td><td rowspan=1 colspan=1>1.6x106 TCID50/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Adenovirus Type 7</td><td rowspan=1 colspan=1>2.81x10}$TCID50/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>8.9x10^³3 TCID5o/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Enterovirus (VR-28 HumanCoxsackievirus)</td><td rowspan=1 colspan=1>8.9x10TCID50/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>HSV Type 1 (HF)</td><td rowspan=1 colspan=1>8.89x106TCID50/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Human coronavirusOC43</td><td rowspan=1 colspan=1>2.81x104TCID50/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Human metapneumovirus(HMPV-27 A2)</td><td rowspan=1 colspan=1>2.8x106 TCID5o/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Human parainfluenza</td><td rowspan=1 colspan=1>2.8x10 TCID5o/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Measles</td><td rowspan=1 colspan=1>1.6x104 TCID5o/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Mumps virus</td><td rowspan=1 colspan=1>1.6x10 TCIDso/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Respiratory syncytial virusVR-26</td><td rowspan=1 colspan=1>1.6 x 10TCID50/mL</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Rhinovirus</td><td rowspan=1 colspan=1>2.8x106 TCID5o/mL</td><td rowspan=1 colspan=1>Negative</td></tr></table>

Of the microorganisms tested, none demonstrated cross-reactivity with the BD Veritor" System for Rapid Detection of Group A Strep test.

# Interfering Substances

Various substances were evaluated for potential interference with the BD Veritor" System for Rapid Detection of Group A Strep test at concentrations comparable to or greater than levels that may be present in patient respiratory samples.

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>ConcentrationTested</td><td rowspan=1 colspan=1>Interferencewith GroupA Result</td></tr><tr><td rowspan=1 colspan=1>4-Acetamidophenol</td><td rowspan=1 colspan=1>10 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>20 mg/mL</td><td rowspan=1 colspan=1>No</td></tr></table>

BD Diagnostic Systems Becton, Dickinson and Company

<table><tr><td rowspan=1 colspan=1>Albuterol</td><td rowspan=1 colspan=1>0.083 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Amantadine</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid chewable tablets</td><td rowspan=1 colspan=1>5% by weight</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Beclomethasone</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Benzocaine throat spray(Cepacol)</td><td rowspan=1 colspan=1>5% by volume</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Blood, type A</td><td rowspan=1 colspan=1>2% (v/V)</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Blood, type B</td><td rowspan=1 colspan=1>2%(v/v)</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Blood, type AB</td><td rowspan=1 colspan=1>2% (v/V)</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Blood, type O</td><td rowspan=1 colspan=1>2%(V/V)</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Budesonide</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Chlorpheniramine maleate</td><td rowspan=1 colspan=1>5 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Dexamethasone</td><td rowspan=1 colspan=1>10 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan (10 mg/mL)</td><td rowspan=1 colspan=1>10 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Dyclonine HCI lozenges(Sucrets)</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Diphenhydramine HCI</td><td rowspan=1 colspan=1>5 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Fexofenadine</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No.</td></tr><tr><td rowspan=1 colspan=1>FluMist</td><td rowspan=1 colspan=1>1% v/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Fluticasone</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Guaiacol Glyceryl Ether</td><td rowspan=1 colspan=1>20 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>10 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Loratidine</td><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Menthol Throat Lozenges</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Mometasone</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Mouthwash (at 5% by volume)Listerine</td><td rowspan=1 colspan=1>5% (v/v)</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Mouthwash Scope</td><td rowspan=1 colspan=1>5% v/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Mouthwash CVS</td><td rowspan=1 colspan=1>5% v/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Mucin, salivary protein, purified</td><td rowspan=1 colspan=1>1 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Nasal Spray</td><td rowspan=1 colspan=1>5% v/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Nasal Spray</td><td rowspan=1 colspan=1>5% v/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Nasal Spray</td><td rowspan=1 colspan=1>5% V/V</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Oseltamivir</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Oxymetazoline</td><td rowspan=1 colspan=1>0.05 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Phenol throat spray(Chloraseptic)</td><td rowspan=1 colspan=1>5% v/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Phenylephrine</td><td rowspan=1 colspan=1>1 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Pseudoephedrine HCI</td><td rowspan=1 colspan=1>20 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Throat drops: CVS</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Throat drops: Pedia Care</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Throat drops: Triaminic</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Triamcinolone</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Zanamivir</td><td rowspan=1 colspan=1>1 mg/mL</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Zicam throat spray (Zn /</td><td rowspan=1 colspan=1>5% v/v</td><td rowspan=1 colspan=1>No</td></tr></table>

BD Diagnostic Systems Becton, Dickinson and Company

<table><tr><td rowspan=1 colspan=1>benzalkonium chloride)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Zinc Lozenges</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1>No</td></tr></table>

Of the substances tested in this study, none exhibited interference when either Group A oositive or Group A negative samples were tested with the BD Veritor ™ System for Rapid Detection of Group A Strep test.

# Media Compatibility

Various types of transport media and culture plate media commonly used in Strep A testing were evaluated for compatibility with the BD Veritor ™ System for Rapid Detection of Group A Strep test. The effects of frozen storage of transport media samples on the stability of the antigen were evaluated in this study. The media tested were: Modified Amies, Modified Stuart's, Normal Saline and Phosphate Buffered Saline. The agar tested were Tryptic Soy Agar with $5 \%$ Sheep Blood and Selective Strep Agar.

Of the four media tested in this evaluation, all four demonstrated the expected results and met the acceptance criteria for both room temperature and overnight frozen storage conditions. Therefore, these four media are all compatible with the BD Group A Strep test. Although the media were non-interfering, dry swab transport and storage is recommended for testing with the BD Group A Strep test. Storage and transport of Strep A specimens in liquid transport will likely dilute the antigen while streaking on solid culture media may remove some organism from the swab, thus resulting in a lower number of bacteria introduced into the extraction reagent.

No interference was seen with the agar tested.

# CLINICAL STUDIES

Performance characteristics for the BD Veritor ™ System for Rapid Detection of Group A Strep were established in a multi-center clinical trial conducted at one clinical laboratory site and four P0C sites during the 2011-2012 respiratory season. A total of 796 prospectively collected specimens were evaluated using the BD Veritor ™ System for Rapid Detection of Group A Strep and bacterial culture. Throat swabs from symptomatic patient were obtained, 51 $8 \%$ from females and $4 8 . 2 \%$ were from males. Specimens from patients five years old or younger comprised 39.1% of the total, with 59.3% from patients 6 to 21 years of age and $1 . 6 \%$ from patients 22 years of age or older.

The performance of the BD Veritor ™ System for Rapid Detection of Group A Strep was determined by comparison to bacterial culture and is presented in the table below.

<table><tr><td rowspan=1 colspan=4>Clinical Performance Data</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Culture   .</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Veritor</td><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>173</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>618</td><td rowspan=1 colspan=1>623</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>647</td><td rowspan=1 colspan=1>796</td></tr><tr><td rowspan=1 colspan=4>Reference Method: CultureSensitivity: 96.6% (92.4%, 98.6%)Specificity: 95.5% (93.6%, 96.9%)</td></tr></table>

<table><tr><td colspan="5" rowspan="1">Clinical Performance Data - By Site</td></tr><tr><td colspan="2" rowspan="1"></td><td colspan="2" rowspan="1">Culture-Reference</td><td colspan="1" rowspan="2">Total</td></tr><tr><td colspan="1" rowspan="1">SiteCode</td><td colspan="1" rowspan="1">Veritor</td><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">N</td></tr><tr><td colspan="1" rowspan="2">ClinicalSite</td><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">82</td></tr><tr><td colspan="2" rowspan="1">Total</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">104</td></tr><tr><td colspan="5" rowspan="1">Reference Method: Culture-ReferenceSensitivity: 100% (83.9%, 100%)Specificity: 97.6% (91.7%, 99.3%)</td></tr><tr><td colspan="1" rowspan="2">POC 1</td><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">57</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">188</td><td colspan="1" rowspan="1">193</td></tr><tr><td colspan="2" rowspan="1">Total</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">191</td><td colspan="1" rowspan="1">250</td></tr><tr><td colspan="5" rowspan="1">Reference Method: Culture-ReferenceSensitivity: 91.5% (81.6%, 96.3%)Specificity: 98.4% (95.5%, 99.5%)</td></tr><tr><td colspan="1" rowspan="2">POC 2</td><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">111</td></tr><tr><td colspan="2" rowspan="1">Total</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">141</td></tr><tr><td colspan="5" rowspan="1">Reference Method: Culture-ReferenceSensitivity: 100% (84.5%, 100%)Specificity: 92.5% (86.4%, 96.0%)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Culture-Reference</td><td colspan="1" rowspan="2">Total</td></tr><tr><td colspan="1" rowspan="1">SiteCode</td><td colspan="1" rowspan="1">Veritor</td><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">N</td></tr><tr><td colspan="1" rowspan="2">POC 3</td><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">106</td><td colspan="1" rowspan="1">106</td></tr><tr><td colspan="2" rowspan="1">Total</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">134</td></tr><tr><td colspan="5" rowspan="1">Reference Method: Culture-ReferenceSensitivity: 100% (84.5%, 100%)Specificity: 93.8% (87.8%, 97.0%)</td></tr><tr><td colspan="1" rowspan="2">POC 4</td><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">36</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">131</td></tr><tr><td colspan="2" rowspan="1">Total</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">139</td><td colspan="1" rowspan="1">167</td></tr><tr><td colspan="5" rowspan="1">Reference Method: Culture-ReferenceSensitivity: 100% (87.9%, 100%)Specificity: 94.2% (89.1%, 97.1%)</td></tr></table>

# Reproducibility

The reproducibility of the BD Veritor ™M System for Rapid Detection of Group A Strep was evaluated at one clinical and two POC sites. The panel was composed of 4 simulated Group A Strep samples. These included high negative samples (i.e. samples containing a very low concentration of Group A Strep), a low positive sample (near the limit of detection), a moderate positive sample and a negative sample. The panel was tested by two operators at each site over five days. The results are summarized below.

<table><tr><td rowspan=1 colspan=5>BD Veritor ™ Group A Strep Reproducibility</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>High negative</td><td rowspan=1 colspan=1>3.3% (1/30)(0.6%, 16.7%)</td><td rowspan=1 colspan=1>0% (0/30)(0%,11.3%).</td><td rowspan=1 colspan=1>0% (0/30)(0%, 11.3%)</td><td rowspan=1 colspan=1>1.1% (1/90)(0.2%,6%)</td></tr><tr><td rowspan=1 colspan=1>Low positive</td><td rowspan=1 colspan=1>96.7% (29/30)(83.3%, 99.4%)</td><td rowspan=1 colspan=1>83.3% (25/30)(66.4%, 92.7%)</td><td rowspan=1 colspan=1>93.3% (28/30)(78.7%, 98.2%)</td><td rowspan=1 colspan=1>91.1% (82/90)(83.4% 95.4%)</td></tr><tr><td rowspan=1 colspan=1>Moderate positive</td><td rowspan=1 colspan=1>100% (30/30)(88.6%, 100%)</td><td rowspan=1 colspan=1>96.7% (29/30)(83.3%, 99.4%)</td><td rowspan=1 colspan=1>100% (30/30)(88.6%, 100%)</td><td rowspan=1 colspan=1>98.9% (89/90)(94%, 99.8%)</td></tr></table>

BD Veritor™ System for Rapid Detection of Group A Strep   

<table><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0% (0/30)(0%, 1.3%)</td><td rowspan=1 colspan=1>0% (0/30)(0%, 11.3%)</td><td rowspan=1 colspan=1>0% (0/30)(0%, 11.3%)</td><td rowspan=1 colspan=1>0% (0/90)(0%, 4.1%)</td></tr></table>

Becton, Dickinson and Company   
C/O Gregory Payne   
Director, Quality Systems and Regulatory Affairs   
10865 Road to the Cure, Suite 200   
San Diego, CA 92121

Re: K122718 Trade/Device Name: BD Veritor™M System for Rapid Detection of Group A Strep Regulation Number: 21 CFR 866. 3740 Regulation Name: Streptococcus spp. Serological Reagents Regulatory Class: Class I Product Code: GTY Dated: January 17, 2013 Received: January 23, 2013

Dear Mr. Payne:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

# Uwe Scherf for

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

510(k) Number: _k122718

Device Name: BD Veritor™ System for Rapid Detection of Group A Stre

# Indications for Use:

The BD Veritor ™ System for Rapid Detection of Group A Strep test is a rapid chromatographic immunoassay for the direct and qualitative detection of Group A Streptococcus antigen from throat swabs of symptomatic patients. It is intended to be used in conjunction with the BD Veritor™" System Reader as an aid in the diagnosis of Group A Strep. All negative test results should be confirmed by bacterial culture because negative results do not preclude Group A Strep infection and should not be used as the sole basis for treatment.

The BD Veritor System for rapid detection of Group A Strep test is intended for use in point-of-care or laboratory settings.

Prescription Use √ AND/OR Over-the-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

![](images/7908e48e2dfe6e8d0a2656b17504670db3101f653fb9dbbcd7738428143328ca.jpg)

Division Sign-Off   
Office of In Vitro Diagnostics and Radlological Health   
510(k) K122718